Investigation of genes influencing response to treatment with Infliximab, Etanercept and Adalumimab in patients with rheumatoid arthritis and related arthropathies.

Trial Profile

Investigation of genes influencing response to treatment with Infliximab, Etanercept and Adalumimab in patients with rheumatoid arthritis and related arthropathies.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms BRAGGSS
  • Most Recent Events

    • 17 Jun 2017 Results identifying Biomarkers to predict the response to etanercept and adalimumab therapy (n=125), presented at the 18th Annual Congress of the European League Against Rheumatism
    • 31 May 2016 Results (n=115) assessing certolizumab drug levels and treatment response published in the Annals of the Rheumatic Diseases
    • 03 Nov 2013 Accrual to date is 73% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top